Colon Cancer, Multiple Myeloma Drug Development Highlights Week in Specialty Pharmacy

Top stories of the week on Specialty Pharmacy Times.

[<a href="//storify.com/pharmacytimes/colon-cancer-multiple-myeloma-drug-development-hig" target="_blank">View the story "Colon Cancer, Multiple Myeloma Drug Development Highlights Week in Specialty Pharmacy" on Storify</a>]

Related Videos
Related Content

Clinical Trial Shows Benefit of Veliparib in ‘BRCA-Like’ Breast Cancer

February 6th 2023

Pharmacy Focus: Psychedelic Pharmacy - Understanding Natural vs. Synthetic Psychedelics

January 13th 2023

FDA Grants Orphan Drug Designation to Belimumab for Systemic Sclerosis Treatment

February 6th 2023

Pharmacy Focus: Public Health Matters- Celebrating American Pharmacist Month Part 2 with Autumn Zuckerman

October 13th 2022

FDA Approves Sacituzumab Govitecan-hziy for HR+/HER2- Metastatic Breast Cancer

February 3rd 2023

Biosimilars Found to Produce Cost Savings Despite Increased Consumption Volume

February 3rd 2023

Clinical Trial Shows Benefit of Veliparib in ‘BRCA-Like’ Breast Cancer

February 6th 2023

Pharmacy Focus: Psychedelic Pharmacy - Understanding Natural vs. Synthetic Psychedelics

January 13th 2023

FDA Grants Orphan Drug Designation to Belimumab for Systemic Sclerosis Treatment

February 6th 2023

Pharmacy Focus: Public Health Matters- Celebrating American Pharmacist Month Part 2 with Autumn Zuckerman

October 13th 2022

FDA Approves Sacituzumab Govitecan-hziy for HR+/HER2- Metastatic Breast Cancer

February 3rd 2023

Biosimilars Found to Produce Cost Savings Despite Increased Consumption Volume

February 3rd 2023

Clinical Trial Shows Benefit of Veliparib in ‘BRCA-Like’ Breast Cancer

February 6th 2023

Pharmacy Focus: Psychedelic Pharmacy - Understanding Natural vs. Synthetic Psychedelics

January 13th 2023

FDA Grants Orphan Drug Designation to Belimumab for Systemic Sclerosis Treatment

February 6th 2023

Pharmacy Focus: Public Health Matters- Celebrating American Pharmacist Month Part 2 with Autumn Zuckerman

October 13th 2022

FDA Approves Sacituzumab Govitecan-hziy for HR+/HER2- Metastatic Breast Cancer

February 3rd 2023

Biosimilars Found to Produce Cost Savings Despite Increased Consumption Volume

February 3rd 2023
About Us
Advertise
Contact Us
Editorial Staff
Privacy Policy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.